The Clinical Trial Inspector is a cutting-edge AI tool that helps researchers and clinicians to derive actionable insights from clinical trial data. Utilizing advanced techniques like Semantic Search and Visual Analytics, it enhances data exploration and decision-making.
claude install geoffkip/Clinical-Trial-InspectorClinical Trial Inspector is an AI agent that helps researchers, clinicians, and analysts explore clinical trial data through semantic search, retrieval-augmented generation, and interactive visualizations. It combines hybrid search (semantic + keyword matching) with multi-filter analytics to discover relevant trials and identify trends across 60,000+ studies. The tool automatically generates inline charts, knowledge graphs, and geospatial maps to reveal connections between studies, sponsors, and medical conditions. Built on LangChain, LlamaIndex, and Google Gemini, it handles complex queries like trial comparisons and translates eligibility criteria into SQL for patient cohort identification.
Sign up for a free Gemini API key at aistudio.google.com/app/api-keys. Paste your key into the Streamlit app deployed on Hugging Face Spaces. Ask natural language questions about trials—the agent automatically selects the right tool (search, analytics, comparison, or cohort SQL generation) based on your query.
Extracting insights from clinical trial data
Visualizing trial results for presentations
Conducting semantic searches for specific trial criteria
Generating reports on clinical trial trends
claude install geoffkip/Clinical-Trial-Inspectorgit clone https://github.com/geoffkip/Clinical-Trial-InspectorCopy the install command above and run it in your terminal.
Launch Claude Code, Cursor, or your preferred AI coding agent.
Use the prompt template or examples below to test the skill.
Adapt the skill to your specific use case and workflow.
Analyze the clinical trial data for [DRUG_NAME] targeting [DISEASE]. Identify key trends in patient response, adverse events, and efficacy metrics. Highlight any outliers or anomalies that warrant further investigation. Suggest potential adjustments to the trial protocol based on these findings.
After analyzing the clinical trial data for 'Nexarib' targeting 'Metastatic Breast Cancer', several key trends emerged. The primary efficacy endpoint, Progression-Free Survival (PFS), showed a median of 10.5 months in the treatment arm versus 7.8 months in the control arm. However, a notable outlier was observed in Cohort B, where 15% of patients experienced a severe immune-related adverse event (irAE) not seen in other cohorts. This could be linked to the concurrent use of corticosteroids, as 80% of these patients were on a medium to high dose. Additionally, the response rate in patients with PD-L1 expression ≥50% was significantly higher (45%) compared to those with lower expression (22%). Based on these findings, I recommend implementing a more rigorous monitoring protocol for irAEs in Cohort B and considering a stratified analysis based on PD-L1 expression levels in future reports.
Prevent blindness with value-based retinal screening
AI-powered front-end development IDE
Create and collaborate on interactive animations with powerful, user-friendly tools.
Medicine delivered in 30 minutes, 24/7
Health-tech solutions for better care
AI-enabled automation of diagnostic radiology workflow
Take a free 3-minute scan and get personalized AI skill recommendations.
Take free scan